Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Safe at Home: Looks Inside for Top Safety Official

This article was originally published in RPM Report

Executive Summary

After a tumultuous, two-year hiatus, FDA finally has a permanent director for the Office of Drug Safety. Gerald Dal Pan, MD, succeeded Victor Raczkowski, ending a drawn out serach for what is increasingly becoming a politically sensitive middle management job within FDA.

You may also be interested in...



Coming to Terms with the FDA Commissioner

The Institute of Medicine thinks FDA needs more stability at the highest level, and thinks a six-year fixed term for the commissioner is a good solution. But FDA's new commissioner doesn't agree.

Drug Safety Reform: Did FDA Buy Time or Trouble?

FDA's senior management is worried that it may have created a political Frankenstein when it called for an outside review of the agency's role in drug safety decisions by the Institute of Medicine. The agency asked for the study to take the heat out of Congressional efforts to split up safety and efficacy reviews. The committee has shown interest in the arguments to create new publicly-funded centers for post-market trials.

Drug Safety Reform: Did FDA Buy Time or Trouble?

FDA's senior management is worried that it may have created a political Frankenstein when it called for an outside review of the agency's role in drug safety decisions by the Institute of Medicine. The agency asked for the study to take the heat out of Congressional efforts to split up safety and efficacy reviews. The committee has shown interest in the arguments to create new publicly-funded centers for post-market trials.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS079617

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel